Tratamiento con rituximab para las miopatías necrosantes autoinmunes asociadas al anti-SRP: caso clínico y revisión de la evidencia

Nóvoa Medina, Francisco Javier; Gutiérrez Martínez, José; González González, Yeray; Romero Díaz, Beatriz; Machín García, Sergio; Rosas Romero, Antonio.
Reumatol. clín. (Barc.) ; 14(6): 379-381, nov.-dic. 2018. ilus
Artículo en Español | IBECS (España) | ID: ibc-176032

Documentos relacionados

  1. Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis.
  2. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
  3. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.
  4. Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect.
  5. Possible role of IL-23 inhibitor in autoimmune hemolytic anemia.
  6. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.
  7. Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease.
  8. Therapy of paraneoplastic pemphigus with Rituximab: A case report.
  9. Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.
  10. Is biological therapy in systemic sclerosis the answer?